Rapid De-escalation of Anti-MRSA Therapy Guided by S. Aureus Nares Screening in Case of Pneumonia

Launched by UNIVERSITY OF BARI ALDO MORO · Jan 25, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to manage pneumonia caused by a type of bacteria called MRSA, which can be particularly serious for hospitalized patients. The researchers want to see if using a nasal test to check for MRSA can help doctors decide when to stop using strong antibiotics that target this bacteria. Right now, guidelines recommend these antibiotics for treating pneumonia, but using them too much can lead to side effects and antibiotic resistance, which means they might not work in the future. By using the nasal test, the goal is to reduce the time patients need these antibiotics, which could also lower hospital stays and costs.

To participate in this trial, patients need to be 18 years or older, be hospitalized for pneumonia, and have started treatment with MRSA antibiotics within the last 48 hours. Certain patients, like those with severe immune problems or other specific infections, won’t be eligible. If they join the study, participants can expect close monitoring to see how quickly they can stop the antibiotics based on the nasal test results while ensuring their overall health is protected. The trial is not yet recruiting participants, but it aims to improve pneumonia treatment and patient outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects 18 years or older.
• • Patients hospitalized at the Azienda Consorziale Policlinico di Bari;
• • Clinical diagnosis of CAP/HAP/VAP;
• • Commitment by the prescribing physician to set an anti-MRSA antibiotic therapy in empirical
• • Enrollement within 48h from the beginning of the empirical anti-MRSA therapy.
• Exclusion Criteria:
• • Febrile neutropenia or severe immunodeficiency;
• • Chronic airway infection (eg cystic fibrosis);
• • Suspect of extrapulmonary infection by MRSA
• • Refusal by the patient or legal guardian;
• • Refusal by the physician in charge of the patient to perform antibiotic de-escalation based on the result of the nasal swab;
• • Enrollment after 48 hours from the beginning of the empirical anti-MRSA therapy.